Unidad de Tumores Sólidos Infantiles

Ewing sarcoma is a rare tumor that affects children and young adults. Approximately 30% of patients diagnosed with this disease will not survive and these mortality rates increase to 80% in patients with disseminated disease or refractory tumors. Even more worrying is the fact that in the last 25 years there have been no significant advances in the treatment of this tumor. For these reasons, we consider it necessary to change the approach and opt for disruptive therapies. In this project, we propose a new gene therapy for the treatment of Ewing sarcoma, based on the expression of therapeutic genes specifically and exclusively in Ewing sarcoma cells.

The TFM offered will be developed in the context of a line of research that pursues the following objectives: i) to identify the therapeutic genes with the greatest potential; ii) to evaluate the use of viral and non-viral vectors; iii) to optimize the specificity of the therapy by improving the functionality of the vectors used. The ultimate goal of the project is to define a therapeutic candidate for a future human clinical trial.